By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Newron Pharmaceuticals 

Via R. Lepetit
Gerenzano      Italy
Phone: 39-02-9668131 Fax: 39-02-96681333



Company News
Newron Pharmaceuticals (NWRN) To Present At The 27th Annual Piper Jaffray Healthcare Conference 11/25/2015 11:11:38 AM
Newron Pharmaceuticals (NWRN) Completes 5.4 Million USD/CHF Private Placement With U.S. Biotechnology/Healthcare Specialist Fund 11/20/2015 9:03:32 AM
Newron Pharmaceuticals (NWRN) And Zambon Release: Swissmedic Approves Xadago (Safinamide) For Use In Parkinson’s Disease 11/13/2015 10:14:39 AM
Newron Pharmaceuticals (NWRN) Announces Planned Pivotal Trial Design For Sarizotan For Patients With Rett Syndrome, A Rare Neurodevelopmental Disease 10/28/2015 11:10:49 AM
Newron Pharmaceuticals (NWRN) Release: Xadago (Safinamide) New Drug Application Late-Cycle Review Meeting Completed With FDA 9/30/2015 12:07:19 PM
Newron Pharmaceuticals (NWRN) Reports Half-Year 2015 Results 9/15/2015 9:28:41 AM
Newron Pharmaceuticals (NWRN) Receives FDA Orphan Drug Designation For Sarizotan For The Treatment Of Rett Syndrome 7/14/2015 8:59:21 AM
Newron Pharmaceuticals (NWRN) Receives Positive Opinion For Orphan Medicinal Product Designation For Sarizotan To Treat Patients With Rett Syndrome From The Committee For Orphan Medicinal Products From European Medicines Agency 6/25/2015 9:38:05 AM
Newron Pharmaceuticals (NWRN) Completes CHF24.3M/US$25.5 Million In Private Placement From Leading EU And US Investors 4/30/2015 1:26:37 PM
Newron Pharmaceuticals (NWRN) Shareholders Authorize Allocation Of Additional Shares To Support Multiple Clinical Programs 3/25/2015 12:57:59 PM